Mary Ellen Frustaci

740 total citations · 1 hit paper
17 papers, 509 citations indexed

About

Mary Ellen Frustaci is a scholar working on Genetics, Immunology and Pharmacology. According to data from OpenAlex, Mary Ellen Frustaci has authored 17 papers receiving a total of 509 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 5 papers in Immunology and 4 papers in Pharmacology. Recurrent topics in Mary Ellen Frustaci's work include Inflammatory Bowel Disease (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Pain Mechanisms and Treatments (4 papers). Mary Ellen Frustaci is often cited by papers focused on Inflammatory Bowel Disease (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Pain Mechanisms and Treatments (4 papers). Mary Ellen Frustaci collaborates with scholars based in United States, Canada and Australia. Mary Ellen Frustaci's co-authors include Maria Alba, Mahesh N. Samtani, P. Fleck, Julio Rosenstock, Priscilla Hollander, Harold Bays, Albert Fung, Ngozi Erondu, Frank Vercruysse and Geert D’Haens and has published in prestigious journals such as Gastroenterology, Neurology and Diabetes Care.

In The Last Decade

Mary Ellen Frustaci

17 papers receiving 497 citations

Hit Papers

Guselkumab for the Treatment of Crohn’s Disease: Inductio... 2022 2026 2023 2024 2022 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
    2022 132 citations William J. Sandborn, Geert D’Haens et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary Ellen Frustaci United States 10 178 165 160 134 123 17 509
Jonathan M. Williams United States 12 112 0.6× 123 0.7× 61 0.4× 39 0.3× 39 0.3× 20 362
Alexandre Fisette Canada 16 74 0.4× 24 0.1× 60 0.4× 192 1.4× 153 1.2× 26 530
Łukasz Hak Poland 10 177 1.0× 81 0.5× 23 0.1× 34 0.3× 87 0.7× 21 563
Sukhbir Dhamrait United Kingdom 14 98 0.6× 298 1.8× 34 0.2× 78 0.6× 58 0.5× 19 593
Toshiharu Onodera Japan 14 138 0.8× 49 0.3× 19 0.1× 187 1.4× 170 1.4× 29 580
HS Randeva United Kingdom 11 78 0.4× 38 0.2× 20 0.1× 107 0.8× 120 1.0× 21 474
Dong-Mee Lim South Korea 14 188 1.1× 52 0.3× 29 0.2× 80 0.6× 61 0.5× 32 486
Susumu Kashine Japan 11 183 1.0× 15 0.1× 36 0.2× 129 1.0× 71 0.6× 14 459
Bartłomiej Kisiel Poland 12 67 0.4× 37 0.2× 35 0.2× 34 0.3× 29 0.2× 41 491
Jennifer L. Kirby United States 14 87 0.5× 58 0.4× 29 0.2× 102 0.8× 72 0.6× 24 529

Countries citing papers authored by Mary Ellen Frustaci

Since Specialization
Citations

This map shows the geographic impact of Mary Ellen Frustaci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Ellen Frustaci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Ellen Frustaci more than expected).

Fields of papers citing papers by Mary Ellen Frustaci

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Ellen Frustaci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Ellen Frustaci. The network helps show where Mary Ellen Frustaci may publish in the future.

Co-authorship network of co-authors of Mary Ellen Frustaci

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Ellen Frustaci. A scholar is included among the top collaborators of Mary Ellen Frustaci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Ellen Frustaci. Mary Ellen Frustaci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Panaccione, Remo, Silvio Danese, Brian G. Feagan, et al.. (2024). EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIES. Gastroenterology. 166(5). 1057b–1057b2. 22 indexed citations
2.
Danese, Silvio, Remo Panaccione, David T. Rubin, et al.. (2022). OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 study. Journal of Crohn s and Colitis. 16(Supplement_1). i026–i027. 18 indexed citations
3.
Sandborn, William J., Geert D’Haens, Walter Reinisch, et al.. (2022). Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology. 162(6). 1650–1664.e8. 132 indexed citations breakdown →
4.
5.
6.
Afzali, Anita, William J. Sandborn, Tadakazu Hisamatsu, et al.. (2021). S748 Early PRO-2 Symptom Remission Following Guselkumab Induction Treatment: Results Through Week 12 of the Phase 2 GALAXI 1 Study. The American Journal of Gastroenterology. 116(1). S344–S345. 1 indexed citations
7.
Rubin, David T., Remo Panaccione, Geert D’Haens, et al.. (2021). S857 Patient-Reported Outcomes of Response and Remission Following Guselkumab Induction Treatment as Measured by the Inflammatory Bowel Disease Questionnaire: Results Through Week 12 of the Phase 2 GALAXI 1 Study. The American Journal of Gastroenterology. 116(1). S400–S400. 1 indexed citations
8.
9.
10.
Danese, Silvio, W. Sandborn, Brian G. Feagan, et al.. (2021). OP28 The effect of guselkumab induction therapy on early clinical outcome measures in patients with Moderately to Severely Active Crohn’s Disease: Results from the phase 2 GALAXI 1 study. Journal of Crohn s and Colitis. 15(Supplement_1). S027–S028. 2 indexed citations
11.
Mayorga, Arthur J., Christopher M. Flores, Jeremiah Trudeau, et al.. (2017). A randomized study to evaluate the analgesic efficacy of a single dose of the TRPV1 antagonist mavatrep in patients with osteoarthritis. Scandinavian Journal of Pain. 17(1). 134–143. 34 indexed citations
12.
Hollander, Priscilla, Harold Bays, Julio Rosenstock, et al.. (2017). Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. Diabetes Care. 40(5). 632–639. 90 indexed citations
13.
Wang, Hao, Gary Romano, Panna Sanga, et al.. (2016). Fulranumab in Patients With Pain Associated With Postherpetic Neuralgia and Postraumatic Neuropathy. Clinical Journal of Pain. 33(2). 99–108. 17 indexed citations
14.
Harrison, Diane D., et al.. (2014). A randomized, double-blind, placebo-controlled 12 week trial of acetaminophen extended release for the treatment of signs and symptoms of osteoarthritis. Current Medical Research and Opinion. 30(11). 2377–2387. 25 indexed citations
15.
Wang, Hao, Gary Romano, Mary Ellen Frustaci, et al.. (2014). Fulranumab for treatment of diabetic peripheral neuropathic pain. Neurology. 83(7). 628–637. 38 indexed citations
16.
Romano, Gary, Mary Ellen Frustaci, Panna Sanga, et al.. (2013). Analgesic efficacy of fulranumab in patients with painful diabetic peripheral neuropathy in a randomized, placebo-controlled, double-blind study. Journal of the Neurological Sciences. 333. e522–e523. 4 indexed citations
17.
Wang, Hao, Gary Romano, Mary Ellen Frustaci, et al.. (2013). Analgesic Efficacy of Fulranumab in Patients with Painful Diabetic Peripheral Neuropathy in a Randomized, Placebo-Controlled, Double-Blind Study (S58.002). Neurology. 80(7_supplement). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan M. Williams Breakdown of academic impact, for papers by Alexandre Fisette Breakdown of academic impact, for papers by Łukasz Hak Breakdown of academic impact, for papers by Sukhbir Dhamrait Breakdown of academic impact, for papers by Toshiharu Onodera Breakdown of academic impact, for papers by HS Randeva Breakdown of academic impact, for papers by Dong-Mee Lim Breakdown of academic impact, for papers by Susumu Kashine Breakdown of academic impact, for papers by Bartłomiej Kisiel Breakdown of academic impact, for papers by Jennifer L. Kirby
Rankless by CCL
2026